The Affiliated Jiangning Hospital of Nanjing Medical University
12
2
3
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.4% vs industry average
25%
3 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
Role: collaborator
Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE-HTN-II)
Role: collaborator
Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE HTN-III)
Role: collaborator
Robotic vs Laparoscopic Gastrectomy for cT4a Gastric Cancer
Role: collaborator
QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer
Role: collaborator
Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial
Role: collaborator
Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer
Role: collaborator
Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Non-Alcoholic Fatty Liver Disease (PARADISE-NAFLD)
Role: collaborator
Different Reperfusion Timing and Ventricular Arrhythmias in STEMI Patients
Role: collaborator
Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML
Role: collaborator
Nutritional Management in Respiratory Critically Ill Patients -an Observational Study in Mainland China
Role: collaborator
Sleep Habits and AMI and Gensini Score
Role: collaborator
All 12 trials loaded